Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,201 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of Home Telemonitoring versus Conventional Follow-up: A Randomized Controlled Trial among Teenagers with Inflammatory Bowel Disease.
Heida A, Dijkstra A, Muller Kobold A, Rossen JW, Kindermann A, Kokke F, de Meij T, Norbruis O, Weersma RK, Wessels M, Hummel T, Escher J, van Wering H, Hendriks D, Mearin L, Groen H, Verkade HJ, van Rheenen PF. Heida A, et al. Among authors: hummel t. J Crohns Colitis. 2018 Mar 28;12(4):432-441. doi: 10.1093/ecco-jcc/jjx169. J Crohns Colitis. 2018. PMID: 29228230 Clinical Trial.
Predicting inflammatory bowel disease in children with abdominal pain and diarrhoea: calgranulin-C versus calprotectin stool tests.
Heida A, Van de Vijver E, van Ravenzwaaij D, Van Biervliet S, Hummel TZ, Yuksel Z, Gonera-de Jong G, Schulenberg R, Muller Kobold A, van Rheenen PF; CACATU consortium. Heida A, et al. Arch Dis Child. 2018 Jun;103(6):565-571. doi: 10.1136/archdischild-2017-314081. Epub 2018 Mar 7. Arch Dis Child. 2018. PMID: 29514815 Free PMC article.
First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial.
Jongsma MME, Aardoom MA, Cozijnsen MA, van Pieterson M, de Meij T, Groeneweg M, Norbruis OF, Wolters VM, van Wering HM, Hojsak I, Kolho KL, Hummel T, Stapelbroek J, van der Feen C, van Rheenen PF, van Wijk MP, Teklenburg-Roord STA, Schreurs MWJ, Rizopoulos D, Doukas M, Escher JC, Samsom JN, de Ridder L. Jongsma MME, et al. Among authors: hummel t. Gut. 2022 Jan;71(1):34-42. doi: 10.1136/gutjnl-2020-322339. Epub 2020 Dec 31. Gut. 2022. PMID: 33384335 Free PMC article. Clinical Trial.
Test Strategies to Predict Inflammatory Bowel Disease Among Children With Nonbloody Diarrhea.
Van de Vijver E, Heida A, Ioannou S, Van Biervliet S, Hummel T, Yuksel Z, Gonera-de Jong G, Schulenberg R, Muller Kobold A, Verkade HJ, van Rheenen PF; CACATU CONSORTIUM. Van de Vijver E, et al. Among authors: hummel t. Pediatrics. 2020 Aug;146(2):e20192235. doi: 10.1542/peds.2019-2235. Epub 2020 Jul 21. Pediatrics. 2020. PMID: 32694147
Randomised clinical trial: First-line infliximab biosimilar is cost-effective compared to conventional treatment in paediatric Crohn's disease.
Vuijk SA, Jongsma MME, Hoeven BM, Cozijnsen MA, van Pieterson M, de Meij TGJ, Norbruis OF, Groeneweg M, Wolters VM, van Wering H, Hummel T, Stapelbroek J, van der Feen C, van Rheenen PF, van Wijk MP, Teklenburg S, Rizopoulos D, Poley MJ, Escher JC, de Ridder L. Vuijk SA, et al. Among authors: hummel t. Aliment Pharmacol Ther. 2024 Apr 21. doi: 10.1111/apt.18000. Online ahead of print. Aliment Pharmacol Ther. 2024. PMID: 38644588
1,201 results